For the first time in decades, the U.S. federal government is seriously reconsidering how it classifies cannabis under the Controlled Substances Act. The review follows widespread state-level legalization and public support for reform, signaling a potential turning point in national drug policy.
Currently, cannabis is listed as a Schedule I substance, a category reserved for drugs viewed as having no accepted medical use and a high potential for misuse. This classification, established in 1970, has remained unchanged despite growing evidence of medical benefits and an expanding legal market across many states.
In 2023, the U.S. Department of Health and Human Services (HHS) recommended that cannabis be reclassified to Schedule III, a category that includes substances with accepted medical uses and lower misuse potential. The Drug Enforcement Administration (DEA) is now reviewing that recommendation before issuing a final decision.
For Complete Cooking STEPS Please Head On Over To Next Page Or Open button (>) and don’t forget to SHARE with your Facebook friends.
